Table 3.

Summary of adverse event data from Phase III trials15

	TMC-278 (686 patients)	Efavirenz (682 patients)	P value
Median treatment duration, weeks	56	56
Grade 2–4 adverse events (%)	16	31	<0.0001
Discontinuation due to adverse events	3	8	0.0005
Most common adverse events
Any neurological adverse events	17	38	<0.0001
Dizziness	8	26	<0.0001
Any psychiatric adverse events	15	23	0.0002
Abnormal dreams/nightmares	8	13	0.0061
Rash (any type)	3	14	<0.0001